Dr Christine Labeur, PhD
Dr Christine Labeur
VHH CMC Subject Matter Expert
Dr Christine Labeur, PhD Joined 272BIO in 2019 as our VHH CMC Subject Matter Expert. Since the start of her scientific career about 35 years ago Christine has been fascinated by the complexity and biochemistry of protein research which has resulted in achieving a broad global expertise of pharmaceutical development and CMC strategies for protein based drugs.
By combining the scientific mindset and expertise in global CMC management processes, outsourcing strategies and Quality Management, she has contributed and worked in various biotech companies, and CDMO’s developing both small and large molecules drugs. She held amongst others, a management position in the CMC department of Ablynx (now Sanofi Pasteur) where the basis for current manufacturing strategies for single domain antibodies were developed. Management functions in various CDMO companies have provided strategic insights into management of outsourced services for pharmaceutical development.
By combining lead selection screening, formulation analytical and process development strategies, aligned with a sound regulatory strategy, several protein biologics (mainly single domain antibodies) were, together with dynamic and cohesive teams, brought successfully into preclinical and clinical studies and finally into commercial products.
Our Management Team leverages their deep industry experience, data-driven insights and strategic innovation to empower our team of advocates who deliver novel healthcare solutions that help customers succeed in an increasingly challenging business climate.